X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs SANOFI INDIA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA SANOFI INDIA GSK PHARMA/
SANOFI INDIA
 
P/E (TTM) x 64.5 32.8 196.5% View Chart
P/BV x 10.4 6.3 165.8% View Chart
Dividend Yield % 1.2 1.4 84.7%  

Financials

 GSK PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
SANOFI INDIA
Dec-16
GSK PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs3,8384,560 84.2%   
Low Rs2,6374,400 59.9%   
Sales per share (Unadj.) Rs354.21,028.5 34.4%  
Earnings per share (Unadj.) Rs39.8129.0 30.8%  
Cash flow per share (Unadj.) Rs42.9186.0 23.1%  
Dividends per share (Unadj.) Rs30.0068.00 44.1%  
Dividend yield (eoy) %0.91.5 61.0%  
Book value per share (Unadj.) Rs236.9753.6 31.4%  
Shares outstanding (eoy) m84.7023.03 367.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.14.4 209.8%   
Avg P/E ratio x81.434.7 234.4%  
P/CF ratio (eoy) x75.524.1 313.5%  
Price / Book Value ratio x13.75.9 229.9%  
Dividend payout %75.452.7 143.1%   
Avg Mkt Cap Rs m274,216103,174 265.8%   
No. of employees `0004.73.6 129.6%   
Total wages/salary Rs m4,8303,592 134.5%   
Avg. sales/employee Rs Th6,387.06,537.7 97.7%   
Avg. wages/employee Rs Th1,028.3991.4 103.7%   
Avg. net profit/employee Rs Th717.1819.8 87.5%   
INCOME DATA
Net Sales Rs m30,00023,686 126.7%  
Other income Rs m728708 102.9%   
Total revenues Rs m30,72824,394 126.0%   
Gross profit Rs m4,1905,281 79.3%  
Depreciation Rs m2631,313 20.0%   
Interest Rs m015 0.0%   
Profit before tax Rs m4,6554,661 99.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,7441,691 103.1%   
Profit after tax Rs m3,3682,970 113.4%  
Gross profit margin %14.022.3 62.6%  
Effective tax rate %37.536.3 103.3%   
Net profit margin %11.212.5 89.5%  
BALANCE SHEET DATA
Current assets Rs m16,74215,673 106.8%   
Current liabilities Rs m7,2026,678 107.9%   
Net working cap to sales %31.838.0 83.7%  
Current ratio x2.32.3 99.0%  
Inventory Days Days5276 68.2%  
Debtors Days Days2122 93.1%  
Net fixed assets Rs m8,6358,098 106.6%   
Share capital Rs m847230 367.8%   
"Free" reserves Rs m19,22217,088 112.5%   
Net worth Rs m20,06917,356 115.6%   
Long term debt Rs m100-   
Total assets Rs m30,03825,400 118.3%  
Interest coverage xNM311.7-  
Debt to equity ratio x00-  
Sales to assets ratio x1.00.9 107.1%   
Return on assets %11.211.8 95.4%  
Return on equity %16.817.1 98.1%  
Return on capital %25.526.9 94.5%  
Exports to sales %024.5 0.0%   
Imports to sales %028.0 0.0%   
Exports (fob) Rs mNA5,801 0.0%   
Imports (cif) Rs mNA6,627 0.0%   
Fx inflow Rs m5287,145 7.4%   
Fx outflow Rs m7,1936,846 105.1%   
Net fx Rs m-6,665299 -2,229.1%   
CASH FLOW
From Operations Rs m2,3603,226 73.2%  
From Investments Rs m3,008-1,555 -193.4%  
From Financial Activity Rs m-5,108-1,818 280.9%  
Net Cashflow Rs m260-147 -177.1%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 60.4 83.9%  
Indian inst/Mut Fund % 10.2 14.4 70.8%  
FIIs % 23.8 14.6 163.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 10.5 146.7%  
Shareholders   102,036 15,184 672.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   PIRAMAL ENTERPRISES  TORRENT PHARMA  PLETHICO PHARMA  DR. REDDYS LAB  ABBOTT INDIA  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jan 22, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - ALEMBIC PHARMA COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS